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  Busulfan is a bifunctional alkylating agent that is used to treat mylogenous 
leukemia. The major elimination pathway of busulfan is through glutathione-S-
transferase (GST) catalyzed conjugation to form glutathione sulfonium conjugate. The 
aim of this work is to elucidate the novel metabolic pathways of busulfan that may 
explain its toxicity. The observed data showed that busulfan is not a substrate for 
CYP450. The sulfonium ion conjugate of busulfan was found to be inactive as it did not 
inhibit GST in human liver cytosol, did not react with 4-(4-nitrobenzyl)pyridine, did not 
induce apoptosis in NCI-H460 cells, and was not stable in basic conditions with a half 
life of 6.0 hours at pH 7.4. The degradation products were identified to be 
tetrahydrothiophene and dehydroglutathione. Dehydroglutathione is a glutathione 
analogue in which the cysteine moiety is replaced by dehydroalanine moiety, which 
makes it a Michael acceptor. This secondary metabolite of busulfan produced 
cytotoxicity against C6 glioma cells and reacted in vitro with sulfhydryl nucleophiles 
such as glutathione and cysteine. An alternative metabolic pathway for the sulfonium ion 
conjugate of busulfan is through the mercapurate pathway which will lead to the 
formation of the cysteine sulfonium conjugate of busulfan (THT-A). THT-A was found 
to undergo a non-enzymatic β-elimination reaction at pH 7.4 and 37 ºC to yield 
tetrahydrothiophene, pyruvate and ammonia. This reaction is accelerated by a) rat liver, 
kidney and brain homogenates, b) isolated rat liver mitochondria, and c) pyridoxal 5'-
phosphate (PLP). A PLP-dependent enzyme in rat liver cytosol that catalyzes a β-lyase 
reaction with THT-A was identified as cystathionine γ-lyase. This unusual drug 
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1.1 Alkylating Agents  
Alkylating agents are anticancer drugs that are formed from a diverse group 
of chemical compounds. These agents have in common the capacity to donate, 
under physiological conditions, alkyl groups to biologically vital macromolecules 
such as DNA. By becoming reactive electrophiles, through the formation of 
carbonium ion intermediates or of transition complexes with the target molecules, 
these agents can form adducts with cellular DNA. Adduct formation may be 
associated with the inhibition of cancer cell growth (1,2). Up to date, these agents 
represent an important treatment for various types of cancer. 
Alkylation of the DNA produces the chemotherapeutic and cytotoxic 
effects of alkylating agents. Bifunctional alkylating agents form covalent bonds 
with the N-7 of guanine on DNA. On the other hand, it must be noted that other 
atoms in the purine and pyrimidine bases of the DNA can be alkylated. This 
includes the N-1 and N-3 of adenine, the N-3 of cytosine, the O-6 of guanine, and 
the phosphate oxygen atoms of the DNA chains. Amino and sulfhydryl groups of 
proteins may also be alkylated. 
 Based on chemical structure, these agents can be classified into five groups 
(3): nitrogen mustards (e.g., chlorambucil and cyclophosphamide), ethylenimines 
(e.g., thiotepa and altretamine), alkyl sulfonates (e.g., busulfan), triazenes (e.g., 
decarbazine), and nitrosoureas (e.g., carmustine, lomustine,and semustine). 
 3
 
1.2 Busulfan  
 Busulfan [1,4-butanediol dimethanesulfonate] is an alkyl sulfonate 
bifunctional alkylating agent. Busulfan has been in clinical use since 1959, and is 
used in the treatment of myeloproliferative disorders. The drug was initially 
introduced (4) to treat chronic myelogenous leukemia (5,6). It was also used in the 
treatment of polycythemia rubra vera (7-9), and essential thrombocythemia 
(10,11). Busulfan is used in high doses in hematopoietic stem cell transplantation 
(12).  
As an alkylating agent, the mechanism of action of busulfan is thought to 
involve DNA alkylation. Busulfan induces dose dependent DNA damage by 
forming an intrastrand cross-link at the 5´-GA-3´ sequence, in addition to 
monoalkylation (13). On the other hand, it was reported that busulfan produced 
interstrand DNA alkylation, but to a lesser extent than other alkanediol 
dimethansulfonates. Monoalkylation was mainly observed on the N-7 of guanine 
(14). It was also suggested that the mechanism of action of busulfan may include 
esterification of the phosphate groups, and changing cell permeability (15). 
1.3 Busulfan Pharmacokinetics  
 The disposition of busulfan is generally well described by a one 
compartment pharmacokinetic model (16-18). Busulfan pharmacokinetics display 
high interpatient and intrapatient variability (16). Some of the factors affecting the 
interpatient-variability were identified as circadian rhythmicity (19), age (19,20), 
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disease state (21,22), drug interaction (23-25), variation in busulfan absorption 
(21),and busulfan bioavailability (26). 
 A circadian rhythmicity in busulfan plasma levels was observed, especially 
in young children, in patients undergoing conditioning therapy prior to stem cell 
transplantation. In some patients a three fold increase in busulfan concentration 
measured during the night compared to that obtained during daytime was observed 
(19). The apparent volume of distribution and clearance of busulfan in children 
was twice that in adults (20). The total body clearance of busulfan decreased with 
increasing age and was significantly higher in young children (7.3 mL min-1 kg-1), 
lower in older children (3.02 mL min-1 kg-1) ,and lowest in adults (2.7 mL min-1 
kg-1) (19). Busulfan pharmacokinetics can be influenced by the underlying disease 
and its status. A higher volume of distribution, a higher clearance, and a longer 
elimination half-life were found among children with lysosomal storage disease 
(21). The systemic exposure of busulfan was significantly higher in children with 
leukemia compared to children with inherited disorders (22). A large 
interindividual variation in the bioavailability of oral busulfan was observed. In 
eight children between the age of 1.5 and 6 years, the bioavailability ranged from 
0.22 to 1.20, and in eight children and adults between 13 and 60 years, it was 
within the range from 0.47 to 1.03 (26). 
Absorption: The absorption kinetics of busulfan from the gastrointestinal tract 
was described by zero (17,18) and first order absorption (16,27,28). Ehrsson et al 
reported zero order absorption of busulfan in patients with chronic myelogenous 
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leukemia following an oral dose of 2, 4, and 6 mg. It was postulated that the zero 
order absorption could be attributed to the zero order dissolution of busulfan (18). 
In addition to description as a zero order process, the absorption of busulfan 
following oral administration was described to follow first order kinetics 
(16,27,28). In a population pharmacokinetics study, a lag time with first order 
absorption was sufficient to describe the absorption of busulfan in seventy two 
patients. Based on this it appears that the kinetics of absorption of busulfan can not 
be described solely by zero or first order kinetics. 
Distribution: Following administration of busulfan, a high percentage of the 
administered dose will be distributed to the liver (29). The central nervous system 
toxicities of busulfan can be attributed to the ability of the drug to cross the blood 
brain barrier. It was reported that 20% of the administered busulfan crossed the 
blood brain barrier in patients treated with high doses of busulfan (30). In the 
human brain, radioactivity of 11C-busulfan reached a maximum within five 
minutes in the cerebellum, cortex, and white matter. Busulfan radioactivity 
showed a cortex to white matter ratio of 1.6. The activity in the cortex declined to 
yield a ratio of 1 within 30 minutes (29). Busulfan concentration in the 
cerebrospinal fluid was detected in all nine children at 3.25-7 hours after the last 
dose of busulfan (1mg/kg every 6 hours over 4 days), a mean cerebrospinal fluid 
to plasma concentration ratio of 0.95 (range, 0.5-1.4) was calculated (17). In 
another study, the cerebrospinal fluid to plasma concentration ratio of busulfan 
was 1.3 (31).  
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Busulfan has a relatively low affinity for plasma proteins. Ehrsson and 
Hassan reported that busulfan irreversibly bound to plasma proteins. The 
percentage of busulfan bound to plasma proteins was 32.4%. Busulfan was found 
to be evenly distributed between blood cells and plasma. The fraction of busulfan 
irreversibly bound to the blood cells was 46.9% (32). In another study, busulfan 
showed nominal protein binding in plasma (7.4%) (31). 
Elimination: The elimination of busulfan is well described by a one-compartment 
pharmacokinetic model (16-18). There was no difference in the reported 
elimination half-life of busulfan between adults and children. The elimination 
half-life of busulfan in adults is 2.75 hours (18,33), while the elimination half life 
of busulfan in children is about 2.5 hours (27,28,34-36). A very low percentage of 
the administered busulfan dose is excreted unchanged in the urine. Ehrsson and 
coworkers reported that only 1% of busulfan is excreted unchanged in  the urine in 
patients with chronic myelocytic leukemia treated with an oral doses of 2, 4, and 6 
mg of busulfan (18). 
1.4 Metabolism of Busulfan. 
 Busulfan is mainly cleared from the body after reaction with glutathione. 
All the identified metabolites of busulfan indicate that the first step in its 
elimination is through conjugation with GSH (Figure 1.1). It was concluded 
initially that the major busulfan clearance pathway is through conjugation with 
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decomposition to tetrahydrothiophene (37). However, Hassan and Ehrsson showed 
that the sulfonium ion of glutathione was the one main metabolite of busulfan in 
isolated perfused rat liver (38).They also showed that this sulfonium ion is either 
cleaved to tetrahydrothiophene or follows the meracpturic acid pathway to 
produce either tetrahydrothiophene or sulfonium ion of N-acetyl-L-cysteine (39). 
After intravenous busulfan administration to rats, the glutathione- sulfonium ion of 
busulfan was identified in the bile (40). 3-Hydroxysulfolane, tetrahydrothiophene 
1-oxide, and sulfolane were identified in urine following intrapleural and oral 
administration of busulfan to rats and human, respectively (31,39).  
Busulfan conjugation with glutathione was catalyzed when incubated with 
human liver cytosol, purified human liver glutathione-S-transferases, and cDNA-
expressed glutathione-S-transferase α1-1. The addition of ethacrynic acid, a non-
specific glutathione-S-transferases inhibitor, to the incubation inhibited the 
enzymatic catalyzed conjugation in a concentration dependent manner (41). 
Czerwinski et al showed that busulfan conjugation with glutathione is catalyzed by 
the major classes of human glutathione-S-transferases (α,μ,π). GSTA1-1 was 
found to be the major isoform contributing to the clearance of busulfan in the body 
(42). 
Role of CYP450 in the metabolism of busulfan: The apparent elimination 
pathway for busulfan from the body is through conjugation with glutathione. 
Busulfan is not an inhibitor of CYP450 3A4 (43). The involvement of CYP450 
enzymes in the metabolism of busulfan was not previously reported. However, 
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some published clinical studies suggested that busulfan undergoes oxidative 
metabolism. It was shown that the clearance of busulfan is induced upon the co-
administration of hepatic enzyme inducing drugs such as phenytoin, 
phenobarbital, and Aroclor 1254 (polychlorinated biphenyls) (23). These drugs 
induce CYPP450 enzymes indicating a role of CYP450 in the metabolism of 
busulfan. It is also worth noting that phenobarbital also induces hepatic 
glutathione-S-transferases. A continuous decrease in the steady-state level of 
busulfan was observed in 40% of phenytoin-treated patients (19). Moreover, 
patients treated with phenytoin along with labeled busulfan demonstrated a 
significantly high clearance, a shorter elimination half life and lower AUCs for the 
last dose of labeled busulfan relative to the first dose, no such effects were 
observed when phenytoin was replaced by diazepam (24). Phenytoin induces both 
CYP450 and γ-glutamyltransferase (44). Itraconazole, an inhibitor of both 
CYP450 and lipoxygenase, significantly decreased the clearance of busulfan 
suggesting the involvement of an oxidative catabolism in the clearance of busulfan 
(25). 
1.5 The Mercapturic Acid Pathway 
The mercapturic acid pathway is a multi-step enzyme catalyzed 
detoxification process by which many electrophiles are detoxified from the body 
(Figure 1.2).  
  The first step of the mercapturic acid pathway is the glutathione-S-transferase 











































Figure 1.2 The Mercapturic Acid Pathway 
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substrates are generally hydrophobic in nature and bear an electrophilic center. 
Epoxides, quinones, lactones, and α−β-unsaturated carbonyl compounds are 
examples of GST substrates (45). GSTs are classified into three major families: 
cytosolic, mitochondrial, and microsomal. The cytosolic and mitochondrial GSTs 
consist of soluble enzymes that share similarities in their three-dimensional fold, 
on the other hand, they have low structural homology with the microsomal GSTs 
which are membrane associated proteins (46).Cytosolic GSTs are classified based 
on their amino acid sequence similarities into seven supergene families including: 
alpha (A), mu (M), theta (T), pi (P), zeta (Z), sigma (S), and omega (O) (47), 
which in turn are subdivided into 16 subunits. Cytosolic GST isoenzymes typically 
share > 40% identity and < 25% identity, within a class and between classes, 
respectively. Mitochondrial GSTs comprise one class of enzymes called kappa, 
while microsomal GSTs comprises four families, with six identified human 
isoenzymes (48).  
   The glutathione S-conjugate is then metabolized to the cysteinylglycine S-
conjugate. This step is catalyzed by the enzyme γ-glutamyltransferase, which 
hydrolyzes the γ-glutamyl moiety from the glutathione S-conjugate. This 
cystienylglycine S-conjugate is subsequently converted to the corresponding 
cysteine S-conjugate, which is catalyzed by the enzymes cysteinylglycine 
dipeptidase or aminopetidase M. The cysteine S-conjugate is N-acetylated by N-
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acetyltransferase to an N-acetyl derivative as a terminal product in the mercapturic 
acid pathway (49). 
  The cysteine S-conjugate could also be a substrate for a group of enzymes 
collectively called cysteine S-conjugate β-lyases. These lyases are a group of 
enzymes that are capable of cleaving the thioether linkage in cysteine S-
conjugates. Such a reaction will lead to the formation of sulfur containing moiety 
and dehydrocystine, which rearrange non-enzymatically to the α-imino acid 
followed by hydrolysis to pyruvate and ammonium. It should be noted that while 
the mercapturic acid pathway is regarded as a detoxification pathway, the 
involvement of β-lyases may lead to the formation of toxic sulfur containing 
metabolites (50).  
   Cysteine S-conjugate β-lyases contain pyridoxal 5´-phosphate as a 
coenzyme. Eleven cysteine S-conjugate β-lyases were identified in mammalian 
tissues, six of which are cytosolic and five are mitochondrial. The cytosolic 
cysteine S-conjugate β-lyases include kynureninase (51), glutamine transaminase 
K (GTK) (52), cytosolic aspartate aminotransferase (CytAspAT) (53), alanine 
aminotransferase (AlaAT) (53), cytosolic branched-chain aminotransfrese 
(BCATc) (54), and γ-cystathionase (55). The mitochondrial β-lyases list includes 
mitochondrial branched-chain aminotransferase (BCATm) (54), mitochondrial 
aspartate (MitAspAT) (56), alanine-glyoxylate aminotransferase isoenzyme II, 
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GABA aminotransferase (57), and a high-Mr β-lyase which also occur in the 
cytosol (58). 
1.6 N,N-Dimethylacetamide (DMA) and Busulfan  
 Busulfan was originally formulated in a tablet dosage form (Myleran®). 
Many studies have shown inter- and intra-individual variability in the disposition 
of busulfan (12). This was attributed in part to the high difference in busulfan 
bioavailability; six times in children and two times in adults (26), or to the 
variation in busulfan absorption (21). One way to overcome this is by formulating 
the drug in a suspension dosage form. Hospital pharmacists usually prepare oral 
busulfan suspension using Myleran® tablets to be administered to children and 
adults with swallowing difficulties (59), although such suspensions are not stable 
at room temperature , but are stable for 30 days at 4◦C (60). Another way is by 
formulating busulfan in an intravenous dosage form. Several IV formulation were 
prepared and evaluated (61-64), and an IV dosage form is currently commercially 
available (Busulfex®).  
Busulfex® Injection is intended for intravenous administration. It is 
supplied as a clear, colorless, sterile, solution in 10 mL single use ampoules. Each 
ampoule of Busulfex® contains 60 mg (6 mg/mL) of busulfan. Busulfan is 
dissolved in N,N-dimethylacetamide (DMA) 33% w/w and polyethylene glycol 
400, 67% w/w. 
 DMA is an organic solvent used in industrial processes such as polymers, 
resins, fibers, films, coating and gums manufacturing. The toxicity of DMA in 
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experimental animals is well established (65). In humans, exposure to DMA 
produced several clinical effects such as delirium, hallucinations, and hepatitis 
(66). An abnormal mental state was observed following exposure to DMA of more 
than 300 mg/kg (67). In a phase Ι clinical study, DMA showed activity as 
anticancer agent for the treatment of adenocarcinoma of the prostate, fibrosarcoma 
of deltoid, multiple myeloma, and adenocarcinoma of colon. Mild, transient 
impairment of liver function was reported as one of the dose limiting toxicities of 
DMA (68). Hepatotoxicity at relatively low chronic exposure (400 mg/kg/day) is 
considered the most important toxic effect of DMA (69), and is believed to be 
caused by reactive metabolites through metabolism by CYP450. In rats, CYP450 
2E1 was identified as the major isoform responsible for the metabolism of DMA 
(70). In humans, the metabolism of DMA produces acetamide and N-
methylacetamide, as identified in the urine of workers exposed to the compound 
(71). It was proposed that the attack on heme by free radical metabolites is 
responsible for the hepatotoxicity of DMA (72). 
DMA constitutes 33% of the solvent system used to solubilize busulfan in 
parenteral dosage form. Busulfan is co-administered with cyclophosphamide in 
high doses in conditioning chemotherapy prior to bone marrow transplantation. 
Cyclophosphamide is a prodrug, and has to be metabolized to the 4-
hydroxycyclophophamide to show activity. This activation is mediated by 
CYP450 2C9, 3A4, and 2B6 (73). Since DMA is known to produce 
hepatotoxicity, and is introduced to the body in high quantity (3.89 g/ busulfan IV 
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dose) in the conditioning chemotherapy, it is possible that DMA could inhibit liver 
CYP450 isoforms, which in turn might reduce the effectiveness of 
cyclophosphamide therapy. 
1.7 Research Objectives 
 Since busulfan might be a substrate for CYP450s, its cytotoxicity might be 
related to its metabolites as well as the drug itself, and the fate of its glutathione 
conjugate is not well characterized, the main research objectives are the following: 
1. To determine the effect of N,N-dimethylacetamide, a major constituent of 
busulfan parenteral formulation, on the catalytic activity of CYP450 3A4, 
2B6, and 2C9 in human liver microsomes. 
2. To investigate the CYP450 oxidative metabolism of busulfan. 
3. To synthesize the glutathione conjugate of busulfan [γ-glutamyl-β-(S-
tetrahydrothiophenium)alanylglycine]. 
4. To characterize the reactivity, alkylating activity, cytotoxicity, and effect on 
glutathione-S-transferases of the glutathione sulfonium conjugate of 
busulfan 
5. To determine the chemical stability of the glutathione sulfonium conjugate 
of busulfan, and characterize the degradation products. 
6. To synthesize the identified degradation product of the busulfan glutathione 
conjugate, and characterize its reactivity and cytotoxicity. 
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7. To synthesize the cysteine S-conjugate of busulfan which could be 
produced in vivo from the glutathione sulfonium conjugate of busulfan 
through the action of mercapturic acid pathway enzymes. 
8. To investigate the chemical formation of the cysteine sulfonium conjugate 
of busulfan, and study its chemical stability. 
9. To determine the β-lyase activity toward the cysteine conjugate of busulfan 















Chapter 2: Experimental Section 
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2.1 Materials  
 Busulfan, L-cysteine, glutathione, Trizma®-HCl, ketoconazole, NADPH, 
ethacrynic acid, thio-TEPA, ammonium acetate, 1-bromo-4-chlorobutane, 
diethylether, deuterium oxide, formic acid, acetone, 4-(4-nitrobenzyl)pyridine, 
triethylamine, butanol, Dowex®-50W, d6-methyl sulfoxide, ammonium hydroxide, 
N,N-dimethylacetamide, testosterone, 6β-hyroxytestosterone, bupropion, 
tolbutamide, sulfaphenazole, and 1-chloro-2,4-dinitrobenzne (CDNB) were 
obtained from Sigma Chemical Company (St. Louis, MO). Acetic acid, sodium 
bicarbonate, dibasic potassium phosphate, monobasic potassium phosphate, 
sodium hydroxide, hydrochloric acid, hexane (optima), acetonitrile (optima), 
methanol (HPLC grade), methylene chloride (optima) were obtained from Fisher 
Scientific (Pittsburgh, PA). Ethanol (200 proof) was obtained from Aaper Alcohol 
and Chemical Co. (Shelbyville, KY). d8-Busulfan was obtained from Cambridge 
Isotope Laboratories, Inc. (Andover, MA). Human liver microsomes, human liver 
cytosol, and Aroclor 1254 induced rat liver microsomes were obtained from In 
Vitro Technologies (Baltimore, MD). 
2.2 Instrumentation 
 UV/VIS absorbance was measured on a Beckman DU 640 
spectrophotometer (Beckman Coulter, Fullerton , CA). NMR spectra were 
obtained using either a Varian Gemini 2000, 300 MHz broadband spectrometer or 
Varian Inova 600 spectrometer (Varian, Palo Alto, CA). 
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LC/MS analysis was performed using a Waters® Alliance 2695 separation 
module equipped with a Waters® 996 Photodiode Array Detector, and coupled to a 
Waters Micromass ZMD mass spectrometer with electrospray ionization 
(Waters®, Milford, MA). Semi-preparative HPLC was carried on a BAS 200A 
HPLC equipped with BAS UV/VIS detector (Bioanalytical Systems, West 
Lafayette, IN). A Waters® Alliance 2695 separation module with a Waters® 2487 
Dual Absorbance Detector was used for HPLC analysis. 
A Finnigan LCQ DECA (ThermoQuest, San Jose, CA) ion trap mass 
spectrometer was used for direct injection mass spectrometry analysis and 
multistage mass spectrometry analysis.  
 A Thomas-Hoover melting point apparatus was used for melting point 
determination. Samples were evaporated to dryness using a Rotavapor-R (Büchi, 
Flawil, Switzerland) rotavap system.  
2.3 In Vitro Metabolism of Busulfan by Liver Microsomes 
2.3.1 Incubation of busulfan with liver microsomes 
 Busulfan at various concentrations (0.8 µM- 800 µM) was incubated with 
various human liver microsomes concentrations (0.2 mg- 1.0 mg) for 10, 20, 30, 
40, and 60 minutes. A typical incubation (total volume 400 µL) consisted of 
busulfan, liver microsomes, Trizma®-HCl buffer (100 mM, pH 7.4), and NADPH 
(1 mM). Reactions were carried in a shaking water bath at 37 ºC, and were started 
with the addition of NADPH, which was omitted in control incubations. Reactions 
were terminated by the addition of 100 µL ice cold acetonitrile containing d8-
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busulfan (5 µg/mL). Samples were then centrifuged at 13,400 rpm for 10 minutes 
to precipitate the protein, and 150 µL of the supernatant were transferred to HPLC 
vials for analysis. In substrate disappearance studies the same incubations 
described above were performed using human liver microsomes or Aroclor 1254 
induced rat liver microsomes, and busulfan concentration of 1, 2, and 4 µM. 
Incubations were carried out for 30 minutes and busulfan concentration in the 
incubation mixture was compared to that in the control (no NADPH). 
 Busulfan was assayed by LC/MS according to the method described by 
Murdter et al (74) with minor modifications. Busulfan was resolved using a Luna 
C8 analytical column (5 µm particle size, 150 x 2 mm i.d.; Phenomenex, Torrance, 
CA), with gradient elution using a binary solvent system composed of 10 mM 
ammonium acetate and 10 mL/L acetic acid (solution A), and acetonitrile (solvent 
B) at flow rate of 0.4 mL/min. Gradients were programmed as follows: 15% 
solvent B at 0 minutes, increased to 45% over 7 minutes, decreased back to 15% B 
over 0.1 minutes, and then left at 15% B for 3 minutes to re-equilibrate. 
Electrospray settings were as follows, capillary voltage 2.0 kV; sample cone, 18 
V; and extraction cone 4.0 V. The source block temperature was set at 120ºC and 
desolvation gas temperature at 300 ºC. The desolvation gas (N2) flow and cone gas 
(N2) flow were 853.8 L/h and 249.4 L/h, respectively. Positive ionization with 
selected ion monitoring was used to detect the ammonium adduct of busulfan (m/z 
264), and d8-busulfan ammonium adduct (m/z 272). 
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2.3.2 Enzymatic Conversion of 1-Chloro-2,4-dinitrobenzene (CDNB) to S-
(2,4-Dintrophenyl)-glutathione (GS-DNB)  
 The glutathione-S-transferase (GST) catalyzed conversion of 1-chloro-2,4-
dinitrobenzene (CDNB) to S-(2,4-dintrophenyl)-glutathione adduct (GS-DNB) 
was assayed according to the method described by Habig et al (75). A typical 
incubation consisted of human liver cytosol (total protein 0.08 mg), reduced 
glutathione (1.0 mM), and CDNB (5.0 - 1000 µM) in 100 mM Trizma®-HCl 
buffer (pH 7.4, total volume 1.0 mL). CDNB was dissolved in methanol, and the 
total methanol concentration was less than 0.5 %. Reactions were initiated by the 
addition of human liver cytosol and carried out at room temperature; human liver 
cytosol was omitted from control incubations. The formation of the GS-DNB 
adduct (ε340 = 9.6 mM-1 cm-1) was determined spectrophotometerically. The 
change in absorbance at 340 nm due to the formation of the GS-DNB adduct was 
followed for five minutes, and the rate of change in absorbance with time (dA/dt) 
was determined. The apparent velocity of the reaction (nmole/mg/min) was 
determined according to the following equation: 
nmole GS-DNB/mg/min = (dA/dt)/[total protein concentration * 0.0096] 
2.3.3 Inhibition of Cytosolic GST Activity by Ketoconazole 
 The enzymatic inhibition of CDNB-SG adduct formation in single donor 
human liver cytosol by the presence of ketoconazole was evaluated. The reaction 
mixture (total volume 1.8 mL) containing Trizma®-HCl buffer (0.1 M, pH 7.4), 
human liver cytosol (total protein 0.08 mg), CDNB (final concentration 1.0 mM in 
methanol), and ketoconazole (final concentration 0, 12.5, 25, 50, 100, and 250 µM 
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in methanol) was incubated at 37 °C. The reaction was started by the addition of 
200 µL of 10mM GSH (final concentration 1.0 mM), and the absorbance was 
monitored for 3 minutes. The non-enzymatic rate (excluding cytosol) was 
subtracted from the enzymatic rate to obtain an apparent velocity calculation. To 
obtain an apparent Ki for ketoconazole inhibition of GST, incubations as described 
above were performed using various concentrations of CDNB (final concentration 
0, 0.125, 0.25, 0.5, and 1 mM), in the presence of ketoconazole (0, 100, 250 µM). 
All determinations were performed at least two times. Reaction rate data was fitted 
to Michaelis-Menton kinetics using Enzyme Kinetics Module (version 1.1.1, 
Systat Software, Inc.). 
2.4 Sulfonium Ion Conjugate of Busulfan  
2.4.1 Synthesis of γ-Glutamyl-β-(S-tetrahydrothiophenium)alanylglycine (γ-E-
THT-AG)  
The sulfonium ion conjugate of busulfan was prepared using the method of 
Marchand et al with some modifications (40). Briefly, reduced glutathione (764 
mg) was dissolved in a 7.5 mL of 1M NaOH, 310 µL of 1-bromo-4-chlorobutane 
were added, and then ethanol was added until a clear solution was obtained 
(approximately 12.0 mL). The reaction mixture was stirred for 1 h at room 
temperature, and then the pH was adjusted to 5.4 by addition of 1M HCl. The 
reaction mixture was stirred for 20 h at room temperature, and then was extracted 
3 times with hexane and 3 times with diethyl ether (80 mL each). The organic 
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layers were discarded and the aqueous phase was evaporated using a rotary 
evaporator. 
γ-E-THT-AG was purified by semi-preparative HPLC equipped with an 
Econosphere C8 column (10 × 250 mm), and a UV/VIS detector set at wavelength 
of 210 nm. Elution was carried out isocratically using 50: 50 methanol/water (v/v) 
at flow rate of 3.0 mL/min. The crude reaction mixture was dissolved in distilled 
water and 100 µL were injected to the LC system. The sulfonium ion band was 
collected, all the collected bands were pooled and the solvent was evaporated 
using rotary evaporation. 
 The sulfonium ion conjugate of busulfan was characterized using mass 
spectrometry and 1H NMR. 1H NMR spectrum was obtained on a sample of 
sulfonium ion conjugate of busulfan dissolved in D2O (10 mg/mL). MS and 
MS/MS spectra were obtained using 1.0 µg/mL of γ-E-THT-AG dissolved in a 
solution of 0.1% formic acid in methanol/water (50/50, v/v). The electrospray 
source (ESI) included: positive ion detection; sheath N2 gas flow rate 20 (arbitrary 
units); spray voltage 5.2 kV; capillary temperature 175.0 °C; capillary voltage 
38.00 V; and tube lens offset 15.0 V. Product (40 mg); 1H NMR (D2O):  δ 2.15-
2.25 (m, 2H); 2.37−2.45 (m, 4H), 2.59-2.64 (m, 2H), 3.48-3.80 (broad m, 7H), 
3.84 (s, 2H), and 5.09 ppm (t, 1H). ESI-MS; M+ m/z 362 (positive ion mode); 
MS/MS: m/z 274, M+- tetrahydrothiophene; m/z 199, M+- tetrahydrothiophene and 
glycine; m/z 145, M+- tetrahydrothiophene and pyroglutamic acid. 
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2.4.2 Stability of γ-E-THT-AG  
 The stability of γ-E-THT-AG at pH 7.4 and 8.0 was determined by 
measuring its rate of disappearance. Stock solutions were made in distilled water 
(2 mg/mL), and further diluted in 100 mM potassium phosphate buffer (pH 7.4 or 
pH 8.0) to produce a final concentration 30 µg/mL. Solutions were incubated in a 
shaking water bath at 37 °C. Aliquots (6.0 µL) taken at 0, 0.25, 0.5, 0.75, 1.0, 1.5, 
2, 3, 4, 5, and 6 h, were diluted in 1.5 mL distilled water and 50-µL aliquots were 
injected into the LC/UV/MS system. The photodiode array detector was 
programmed to scan between 200 and 300 nm, and a mass spectrometer was 
programmed to utilize electrospray ionization in a positive ion mode with selected 
ion recording of m/z 362 for γ-E-THT-AG. The mobile phase consisted of 
methanol/water (50/50, v/v) pumped at 0.4 mL/min through an Agilent Zorbax 
SB-NC C18 (150 x 4.6 mm) reversed phase column (Agilent, Santa Clara, CA). Ion 
optics (ESP+) were as follows: capillary, 3.0 kV; sample cone, 21 V; and 
extraction cone, 3.0 V. The source block temperature was set at 120°C and 
desolvation gas temperature was set at 300°C. The desolvation gas flow and cone 
gas flow (both N2) were 473 L/h and 117 L/h, respectively. 
Non-enzymatic breakdown of γ-E-THT-AG via a β-elimination reaction is 
predicted to generate γ-glutamyldehydroalanylglycine. The appearance of vinyl 
protons associated with this tripeptide was detected by NMR. γ-E-THT-AG (14 
mg) was dissolved in 1.0 mL of D2O and proton spectra were recorded to follow 
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chemical changes upon the addition of dibasic phosphate (15 mg; final pD ~8.0) 
and incubation for 12 h correct at 37 °C. 
2.4.3 Relative Alkylation Reactivity of γ-E-THT-AG  
 The method of Linford et al (76) was used to determine the relative 
alkylating activity of busulfan and γ-E-THT-AG. Aliquots of busulfan (15 mg/mL 
in acetone) and γ-E-THT-AG conjugate (15 mg/mL in water) stock solution were 
introduced to a series of round-bottom test tubes (total volume of acetone or water 
250 µL), followed by 250 µL of distilled water, 500 µL of 2.5% 4-(4-
nitrobenzyl)pyridine, and 500 µL 1.0 M acetic acid. Final concentrations were 
0.25, 0.5, 1.25, 2.5, 5.0, 7.5, 10 µg/mL. Busulfan and γ-E-THT-AG were omitted 
from controls, and thio-TEPA in methanol (250 µg- 1.0 mg) was used as positive 
control. All tubes were capped, vortexed, and incubated at 56 ºC in a water bath 
for 20 minutes. Each tube was then allowed to cool at room temperature. After 
cooling, 2.0 mL of triethylamine in propylene glycol (50/50, v/v) was added to 
each tube, vortexed, allowed to react for 2 minutes, and the absorbance at 580 nm 
was determined spectrophotometerically. 
2.4.5 Cytotoxicity of γ-E-THT-AG 
Apoptosis : Human lung cancer epithelial NCI-H460 cells were cultured in 
RPMI-1640 medium supplemented with 5% fetal bovine serum and 2 mM 
glutamine. Antibiotics added to the medium were 100 U/mL penicillin and 100 
µg/mL streptomycin. Cell cultures were maintained in a humidified atmosphere of 
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95% air and 5% CO2 at 37 °C. Cells were passaged at preconfluent densities by 
the use of a solution containing 0.05% trypsin and 0.5 mM EDTA.  
 Busulfan and γ-E-THT-AG, in the concentration 0-400 µg/mL, were 
incubated with NCI-H460 cells for 24. Busulfan was dissolved in DMSO while 
the sulfonium ion conjugate of busulfan was dissolved in phosphate buffer (pH 
7.4). Apoptosis was quantified by assessing the characteristic morphological 
changed in the apoptotic cells using Hoechst 33342 staining. Hoechst 33342 binds 
specifically to the A-T base region of DNA and emits the fluorescence. At the end 
of the incubation, cells were washed twice with PBS (pH 7.4), stained with 
Hoechst 33342 (10 µg/ml in PBS) for 3 min, and then photographs were taken at 
X200 magnification under a fluorescent microscope (Olympus, Tokyo, Japan). 
The number of attained cells per more than 200 cells was counted to assess the 
proportion of cells with nuclear fragmentation. The experiment was repeated three 
times.  
2.4.6 Effect of γ-E-THT-AG on glutathione-S-transferase (GST) 
 The effect of γ-E-THT-AG on the enzymatic activity of glutathione-S-
transferases was determined at room temperature in 1 mL (final volume) of 100 
mM Trzma®-HCl buffer (pH 7.4) containing 1 mM GSH, 100 mM CDNB, human 
liver cytosol (final protein concentration of 0.08 mg), and γ-E-THT-AG (1-100 
µM). Reactions were initiated by the addition of human liver cytosol which was 
omitted in control incubations. Ethacrynic acid (2.5-200 µM) was used as a 
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positive control. Both ethacrynic acid and CDNB were dissolved in methanol and 
the total methanol concentration was less than 1.0%. The formation of GS-DNB 
adduct was followed spectrophotometerically and the apparent reaction velocity 
was determined as described above. 
2.5 Busulfan-Cysteine Sulfonium Ion Conjugate  
2.5.1 Synthesis of S-β-Alanyltetrahydrothiophenium (THT-A) 
The busulfan-cysteine sulfonium conjugate was prepared according to the 
method of Roberts et al (37) with some modifications. 1-bromo-4-chlorobutane 
was used instead of dibromobutane. Briefly, 1-bromo-4-chloro butane (2.16 g) 
were added to ethanol: water (70: 30, v: v) solution. Five mL of 4 N NaOH 
containing 1.57 g of cysteine were then added, and the reaction was allowed to 
stand at room temperature over night. The reaction mixture was then filtered and 
the filtrate was discarded. The product was crystallized using 0.5 L of acetone. 
THT-A was characterized by MS, MS/MS, and NMR as described above for γ-E-
THT-AG. Elemental analysis showed that the THT-A product contained one 
equivalent of Cl¯, one equivalent of Br¯ and one equivalent of H2O. Product (1.0 
g); 1H NMR (D2O): δ  2.30-2.52 (m, 4H), 3.52-3.64 (m, 4H),  3.68-3.80 (m, 2H), 





2.5.2 Chemical Stability of THT-A 
The chemical stability of THT-A at pH 7.4 and 8.0 was determined by 
measuring its rate of disappearance. Stock solutions were made in distilled water 
(2.0 mg/mL), and further diluted in 100 mM potassium phosphate buffer (pH 7.4 
or pH 8.0) to produce a final concentration of 100 µg/mL. Both solutions were 
incubated in a shaking water bath at 37 °C. Aliquots (6 µL) taken at 0, 0.25, 0.5, 
0.75, 1.0, 1.5, 2, 3, 4, 5, and 6 h, were diluted in 1.5 mL distilled water and 50 µL 
aliquots were injected into the LC/UV/MS system. The photodiode array detector 
was programmed to scan between 200 and 300 nm, and the mass spectrometer was 
programmed to utilize electrospray ionization in a positive ion mode with selected 
ion recording of m/z 176. The mobile phase consisted of methanol-water (50:50, 
v/v) pumped at 0.4 mL/min through an Agilent Zorbax SB-NC C18 150 x 4.6 mm 
reversed phase column. Ion optics (ESP+) were as follows: capillary, 3.0 kV; 
sample cone, 21 V; and extraction cone, 3.0 V. The source block temperature was 
set at 120 °C and desolvation gas temperature was set at 300 °C. The desolvation 
gas flow and cone gas flow (both N2) were 473 L/h and 117 L/h, respectively.  
2.5.3 Reaction of cysteine with busulfan. 
 Aliquots (50 µL) of busulfan stock solution (200 µg/mL in acetonitrile) 
were mixed with 4.9 mL of 100 mM potassium phosphate buffer (pH 8.0), then 50 
µL of cysteine stock solution (40 mg/mL in water) were added. The mixture was 
vortexed for one minute and incubated at 37 ºC. Aliquots (100 µL) taken at 0, 30, 
60, 90, 120, and 180 minutes, were diluted with 100 µL acetonitrile containing d8-
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busulfan (5 µg/mL), and transferred to HPLC vials. Busulfan was assayed as 
described earlier. 
2.5.4 Enzymatic Conversion of THT-A to Pyruvate and Ammonium 
  THT-A contains a good leaving group and could undergo a β-elimination 
reaction to produce pyruvate and ammonium. To evaluate the potential for a β-
elimination reaction, THT-A was incubated with rat liver, brain and kidney 
homogenate, and purified cystathionine-γ-lyase. All experiment procedures in this 
section were done by Dr. Arthur Coopers’ group at Weill Medical College of 
Cornell University. 
Preparation of rat tissue homogenates: All experimental procedures were 
approved by the Weill Medical College of Cornell University Institutional Animal 
Care and Use Committee (Protocol 0505-367A). Six-month old male Fisher x 
Brown Norway F1 rats were used. The animals were fed ad libitum and had full 
access to water. Rats were sacrificed by decapitation. Liver, kidneys and 
forebrains were removed and separately immersed in 50 mL of ice-cold isolation 
buffer containing 300 mM sucrose, 10 mM HEPES, 0.5 mM EGTA, and 0.5% 
(w/v) fatty acids-free bovine serum albumin (pH adjusted to 7.4 with Tris base). 
The tissues were pre-chilled for ~5-6 minute. Each tissue sample was separately 
cut into small pieces with scissors and homogenized in a ~10-fold volume of 
isolation buffer supplemented with protease-inhibitor cocktail (1/100 dilution). 
Liver and kidney tissues were homogenized using a Potter homogenizer. The 
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brains were homogenized using a Dounce homogenizer. All steps were carried out 
at 0-4 °C. The homogenates were divided into several aliquots and stored at -20 
°C. In some experiments, the liver homogenate was fractionated into cytosolic and 
mitochondrial fractions and stored at -20 °C (77). All tissue samples were freeze-
thawed several times. In other experiments, aliquots of the tissue preparations 
were centrifuged at 1,000 g for 5 min and 0.1 mL of each supernatant was filtered 
through a centrifugal filter device with a 10-KDa cut-off membrane (Microcon 
Ultracel YM-10, Millipore Corporation, Bedford, MA). The pass through is not 
expected to contain PLP-dependent enzymes, but is expected to possess free PLP 
and free pyridoxal.  
Protein measurements: Protein concentrations were determined using a micro-
Biuret assay kit obtained from Sigma Chemical Company (St. Louis, MO). Bovine 
serum albumin was used as a standard. 
Purifcation of Cystathionine γ-lyase (γ-cystathionase; 2.4 U/mg; 1.32 U/mL) was 
purified from rat liver cytosol by a method modified from that of Hargrove and 
Wichman (78) as described by Pinto et al. (79) and stored frozen at -20°C. Bovine 
liver glutamate dehydrogenase (GDH) (40 U/mg in 40% glycerol) was obtained 
from Boehringer Mannheim (Mannheim, Germany). Rat liver mitochondrial 
aspartate aminotransferase [mitAspAT; 1.35 mg/mL in 20 mM Tris-HCl buffer, 
pH 8.3, containing 0.1 mM EDTA, 150 mM NaCl and 0.2% (w/v) sodium azide; 
410 U/mg of protein at 37 °C] was a generous gift from Dr. Ana Iriarte, University 
of Missouri-Kansas, Kansas City, MO. Rat kidney glutamine transaminase K 
 31
 
(GTK; 5 U/mg in 20% glycerol; 0.18 U/mL) was purified from the cytosolic 
fraction of rat kidneys as described previously (80). 
Enzyme assays. Cystathionine γ-lyase activity was assayed by a slight 
modification of the procedure of Cooper and Pinto (81) in which α-ketobutyrate 
formed from L-homoserine was measured as its 2,4-dinitrophenylhydrazone. The 
standard reaction mixture (20 μL) contained 100 mM potassium phosphate buffer 
(pH 7.4), 20 mM L-homoserine and enzyme. The blank contained enzyme but no 
L-homoserine. After incubation at 37 °C, the reaction was terminated by the 
addition of 10 μL of 5 mM 2,4-dinitrophenylhydrazine in 2 M HCl. After a further 
10 minutes incubation, 170 μL of 1 M NaOH was added and the absorbance at 
430 nm was read within 2 minutes of addition of alkali against a blank carried 
through the same procedure. The extinction coefficient of α-ketobutyrate 2,4-
dinitrophenylhydrazone under these conditions is 15,000 M-1cm-1. L-Homoserine 
is a convenient γ-lyase substrate of cystathionine γ-lyase (82) that is less expensive 
than L-cystathionine.  
β-Lyase reactions with THT-A were measured in a reaction mixture (20 
μL) containing 100 mM potassium phosphate buffer (pH 7.4), 5 mM THT-A and 
enzyme. After incubation at 37 °C the reaction was stopped by addition of 10 μL 
of 5 mM 2,4-dinitrophenylhydrazine in 2 M HCl. After a further 10 minutes 
incubation, 170 μL of 1.0 M NaOH was added and the absorbance at 430 nm was 
read within 2 minutes. The extinction coefficient of pyruvate 2,4-
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dinitrophenylhydrazone under these conditions is 16,000 M-1cm-1. The blank 
contained no enzyme or enzyme source added just before addition of 2,4-
dinitrophenylhydrazine reagent. A blank containing no enzyme takes into account 
the small amount of pyruvate generated non-enzymatically from 5 mM THT-A. 
Most cysteine S-conjugate β-lyases that catalyze a non-physiological β-
elimination reaction if a strong electron-withdrawing group is attached at the 
sulfur of the cysteine S-conjugate are aminotransferases (49,83). For these 
enzymes, a transamination reaction usually competes with the β-lyase reaction. A 
half transamination results in the formation of the pyridoxamine 5'-phosphate form 
of the coenzyme. The enzyme in the pyridoxamine 5'-phosphate form cannot 
support a β-lyase reaction. For the enzyme to catalyze an uninterrupted β-lyase 
reaction an α-keto acid substrate (or PLP) must be present in the assay mixture to 
ensure continuous presence of the PLP form of the enzyme (52,84). To determine 
whether β-lyase-catalyzed reactions with THT-A are dependent on α-keto acids, 
in some experiments the β-lyase reaction mixture was supplemented with 0.5 mM 
KMB or 0.5 mM KG. KMB is good α-keto acid substrate of glutamine 
transaminase K (GTK), an enzyme that catalyzes a strong β-lyase reaction with the 
cysteine S-conjugates S-(1,1,2,2-tetrafluoroethyl)-L-cysteine (TFEC) and S-(1,2-
dichlorovinyl)-L-cysteine (DCVC) (49,83,85). KG is a good α-keto acid substrate 
of most other mammalian aminotransferases, including mitAspAT, an enzyme that 
 33
 
also exhibits β-lyase activity toward TFEC and DCVC (56). GTK and mitAspAT 
activities were measured as described by Cooper (80). 
Ammonium was measured with GDH. To the solution containing 
ammonium (20 μL) was added 180 μL of a reaction mixture containing 100 mM 
potassium phosphate buffer (pH 7.4), 0.1 mM EDTA, 10 mM KG, 0.25 mM 
NADH, 0.01 mM ADP and 4 U of GDH.  The decrease in absorbance at 340 nm 
(ε = 6.22 x 103 M-1 cm-1) due to oxidation of NADH to NAD+ was continuously 
measured at 37 °C. The reaction was complete in 20 minutes. 
All spectrophotometric measurements were carried out with a SpectraMax 
96-well plate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).  A 
unit of enzyme activity (U) is defined as the amount of enzyme that catalyzes the 
formation of 1 μmol of product per min at 37 ºC. 
2.6 γ-Glutamyldehydroalanylglycine (dehydroglutathione) 
2.6.1 Synthesis of dehydroglutathione  
  Dehydroglutathione was synthesized through the elimination of 2,4-
dinitrothiophenolate from S-(2,4-dinitrophenyl)glutathione as described by 
Carthew et al (86). S-(2,4-Dinitrophenyl)glutathione was synthesized with minor 
modification of the method of Patchornik et al (87). Briefly, 2.02 mg (10 mmol) of 
1-chloro-2,4-dinitrobenzene were dissolved in 20 mL of methanol and added drop 
wise over 30 minutes to a solution containing 3.07 g (10 mmol) reduced 
glutathione dissolved in 40 mL of 1N NaHCO3. The solution was then stirred at 
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room temperature for one hour, filtered, and the product was precipitated by the 
addition of 1M HCl. The yellow precipitate was collected by vacuum filtration and 
dried. S-(2,4-Dinitrophenyl)glutathione was recrystallized from hot water. The 
yellow crystals were characterized by MS, MS/MS, and 1H NMR. Product (2.0 g) 
had m.p. 189-191°C. 1H NMR (DMSO-d6): δ 1.84 (m, 1H), 1.95 (m, 1H), 2.32 (m, 
2H), 3.31-3.38 (m, 2H), 3.60-3.65 (m, 1), 3.73 (m, 1H), 4.61 (m, 1H), 7.97 (d, 
1H), 8.46 (d, 1H), 8.71 (d, 1H), and 8.87 ppm (m, 2H). ESI-MS; MH+ m/z 474 
(positive ion mode); MS/MS: m/z 399, MH+- glycine; m/z 345, MH+- 
pyroglutamic acid. 
  S-(2,4-Dinitrophenyl)glutathione was then used to prepare 
dehydroglutathione. One gram of S-(2,4-dinitrophenyl)glutathione was dissolved 
in 50 mL of 0.5 M NaOH, and the solution was stirred at room temperature for 30 
minutes. The solution was then extracted five times with butanol (20 mL each), 
the organic layers were discarded and the aqueous layer was mixed with 3 grams 
of Dowex®-50W ion exchange resin (hydrogen form) to remove Na+. The pH of 
the solution dropped from 12.4 to ~ 4.0. The aqueous solution was evaporated, and 
a light brown solid was collected (yield 60.4%). Unlike the method of Carthew et 
al, the obtained product was neither decolorized by charcoal nor recrystallized 
from ethanol. The product was characterized by mass spectrometry and 1H NMR 
spectrometry, and its purity was determined by quantitative 13C NMR. Product 
(0.51 g). 1H NMR (D2O): δ 2.06 (m, 2H), 2.48 (m, 2H), 3.69 (m, 1H), 3.81 (s, 2H), 
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and 5.62 ppm (d, 2H). ESI-MS; MH+ m/z 274 (positive ion mode); MS/MS: m/z 
256, MH+- water; m/z 199, MH+- glycine. 
2.6.2 Reactivity of Dehydroglutathione Toward Nucleophiles 
 The ability of dehydroglutathione to react in the body with nucleophiles 
such as cysteine and glutathione was evaluated. The adduct structure was 
elucidated by mass spectrometry and the rate of adduct formation was determined 
by 1H NMR. 
Cysteine-dehydroglutathione adduct: A solution of dehydroglutathione in water 
(10 µmol, 0.5 mL) was mixed with a solution of cysteine in 1% NH4OH (10 µmol, 
0.5 mL), and the mixture was held overnight at 37 ºC in a water bath. The mixture 
was further diluted 200 fold in a solution of 1% FA in methanol/water (50/50, 
v/v), and analyzed by mass spectrometry. The rate of the reaction was determined 
by 1H NMR through following the disappearance of the vinylic proton doublet 
(between 5-6 ppm) of the dehydroglutathione upon the addition of cysteine. 
Dehydroglutathione (0.05 mmol) and cysteine (0.05 mmol) were dissolved in 100 
mM potassium phosphate buffer prepared in D2O (pD 8.0). Both solutions were 
incubated at 37 ºC for 30 minutes, then 0.5 mL of each solution was mixed and 
transferred to NMR tube. The NMR probe was set at 37 ºC, the first 1H NMR 
spectrum recorded was designated as time zero, and a new spectrum was recorded 
every 5 minutes for 30 minutes. 
Glutathione-dehydroglutathione adduct: 0.5 mL of a solution of glutathione in 1% 
NH4OH (18.3 mmol) were mixed with 0.5 mL of dehydroglutathione in water 
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(36.6 mmol), the mixture was incubated at 37 ºC for 12 hours. The solution was 
diluted 1000 fold in a solution of methanol/water (50/50, v/v, 1% formic acid). 
Structure elucidation of the adduct was performed in MS, MS/MS, and MS3. 
2.6.3 In Vitro Cytotoxicity of Dehydroglutathione 
 C6 rat glioma cells were obtained from the American Type Culture 
Collection (Manassas, VA), and maintained in DMEM-F12 (1:1) medium (Gibco, 
Grand Island, NY) supplemented with 1% of antibiotic-antimycotic mixture 
(Gibco, Grand Island, NY) and 10% fetal calf serum (FCS; Sigma, St. Louis, MO) 
at 37°C under an atmosphere of 5% CO2-95% air. For toxicity experiments 5x104 
cells per well were seeded into Primaria 12-well cluster dishes in 0.5 ml of 
DMEM-F12/FCS medium, and allowed to attach to the substratum overnight. 
Subsequently, the cells were exposed to busulfan and dehydroglutathione for 24 h. 
Busulfan was added as DMSO (1% final concentration) solution and cultures 
treated with DMSO alone served as controls. Dehydroglutathione was added as 
aqueous solution. Cell viability was assessed by the trypan blue exclusion test. 
Briefly, the medium was removed, the adhering cells were trypsinized and stained 
with trypan blue. Viable, dye excluding cells were counted in a hemocytometer. 
2.7 Effect of N,N-Dimethylacetamide (DMA) on the Catalytic Activity of 
CYP450 3A4, 2B6, and 2C9 in Human Liver Microsomes 
  The effect of DMA on CYP450 3A4, 2B6, and 2C9 isoforms in human 
liver microsomes was determined by studying its ability to inhibit the metabolism 
of known substrate markers for each isoform. 
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2.7.1 CYP450 3A4 Assay 
 Testosterone 6β-hydroxylation was measured to determine the inhibitory 
effect of DMA on CYP450 3A4. A typical incubation consisted of human liver 
microsomes (0.2 mg), testosterone (40 µM), DMA (0-25 mM), NADPH (1 mM) 
in a total volume of 500 µL of 50 mM potassium phosphate buffer (total methanol 
< 2%). The incubations were done in a shaking water bath maintained at 37 ºC. 
For control incubations, NADPH was omitted. Reactions were started by the 
addition of NADPH, and were stopped after 10 minutes by the addition of 2.0 mL 
of methylene chloride. Each sample was then vortexed for 1 minute and 
centrifuged for 10 minutes at 3,000 rpm. The aqueous layer (upper layer) was 
discarded, and 1.8 mL of the organic layer was transferred to a clean culture tube. 
The organic layer was evaporated under a gentle stream of nitrogen, and the 
residue was reconstituted in 200 µL of 50% methanol, and 10 µL were injected 
into the HPLC. 
Testosterone and 6β-hydroxytestosterne were resolved using an Agilent 
Zorbax SB-NC 5 µm C18 HPLC column (4.6 x 150 mm) kept at 40 ºC, and a 
binary linear gradient elution. The method used was described by Naritomi et al 
(87,88), the mobile phase consisted of solvent A (methanol: water, 20:80, v:v) and 
solvent B (methanol: acetonitrile, 91:9, v:v). The solvent program was as follows: 
30% B 0-1 min, 30-38% B 1-18 min, 38-100% B 18-18.1 min, 100% B 18.1-20 
min. The flow rate was 1.0 mL/min, and elution was detected at 238 nm. 6β-
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Hydroxytestosterne formation was quantified by comparison of its peak intensity 
with that of authentic standard. 
2.7.2 CYP450 2B6 Assay 
Bupropion hydroxylation was used to evaluate the inhibitory effect of 
DMA on CYP450 2B6. Concentrated stock solution of bupropion was prepared 
and diluted in methanol. The incubation mixture consisted of human liver 
microsomes (0.2 g), bupropion (500 µM), DMA (0-25 mM), and NADPH (1 mM) 
in a final volume of 500 µL of 50 mM potassium phosphate buffer. The incubation 
was carried out in a shaking water bath maintained at 37 ºC for 30 minutes. For 
controls NADPH was omitted, and for positive control DMA was replaced by 
thio-TEPA (50 µM). Reactions were started by the addition of NADPH, and were 
stopped by the addition of 100 µL of ethyl acetate. Sample handling and LC/MS 
analysis was carried out as described by Arellano et al (89). Briefly, 100 µL of 
0.25 N NaOH were added to each sample. After mixing for one minute, 900 µL of 
ethyl acetate were added, samples were then vortexed and centrifuged at 3,000 
rpm for two minutes. After centrifugation, 850 µL of the organic layer were 
transferred to a clean culture tube containing 850 µL of 0.5% formic acid. Samples 
were mixed vigorously and centrifuged at 3,000 rpm for two minutes. The organic 
layer was discarded and 50 µL of the aqueous layer were transferred to an HPLC 
vial for analysis.  
LC/MS analysis was performed on Water SymmetrySheildTM 5 µm C18 (3.9 
x 150 mm). The mobile phase consisted of a mixture of 0.1% formic acid: 
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methanol (75: 25, v: v), the flow rate was set at 0.2 mL/min, and the injection 
volume was 5 µL. The mass spectrometer was programmed in a positive ion mode 
with a selective ion recording of m/z 256 for hyroxybupropion. Ion optics (ESP+) 
were as follows: capillary, 1.98 KV; sample cone, 13 V; and extraction cone, 7.0 
V. The source block temperature was set at 120 ºC. The desolvation gas flow and 
cone gas flow (both N2) were 353.5 L/h and 192.6 L/h, respectively. 
2.7.3 CYP450 2C9 Assay 
Tolbutamide 4-methylhydroxylation was used to evaluate the inhibitory 
effect of DMA on CYP450 2C9. Human liver microsomes (0.2 g) were incubated 
at 37 ºC in 500 µL (final volume) containing 50 mM potassium phosphate buffer 
(pH 7.4), tolbutamide (1 mM), DMA (0-25 mM), and NADPH (1 mM). The 
reactions were started with the addition of NADPH and stopped after 40 minutes 
by the addition of 100 µL of ice cold 4.0 N HCl. NADPH was omitted in control 
incubations and sulfaphenazole (50 µM) was used as a positive control. 
Tolbutamide and sulfaphenazole solution were prepared and diluted in methanol. 
Samples were handled as described by Lasker et al (90). After the reaction was 
stopped, 1.5 mL of ethyl acetate were added, the samples were then vortexed and 
centrifuged for 5 minutes at 3,000 rpm. One mL of the organic layer was 
evaporated to dryness in a Savant SC100 Speed Vac Concentrator (Farmingdale, 
NY), and the residue was reconstituted in 200 µL methanol. 
A semiquantitative LC/MS method was developed for the detection of 4-
methylhydroxytolbutamide. Elution was carried on a YMCTM Pro C18 (2.0x50 
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mm) column, using a mixture the 0.1% formic acid: methanol (60: 40, v: v) at 0.2 
mL/min, with 5 µL injection volume. The mass spectrometer was programmed in 
a positive ion mode with a selective ion recording m/z 286 for 4-methylhyroxy 
tolbutamide. Ion optics (ESP+) were as follows: capillary, 1.75 KV; sample cone, 
17 V; and extraction cone, 7.0 V. The source block temperature was set at 120 ºC. 












Chapter 3: Results 
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3.1 In Vitro Metabolism of Busulfan by Liver Microsomes 
 Incubation of busulfan with human liver microsomes did not result in the 
appearance of detectable busulfan metabolites as determined by LC/MS analysis. 
In substrate disappearance studies, busulfan (1, 2, and 4 µM) was incubated with 
both human liver microsomes and Aroclor-1254 induced rat liver microsomes. 
The obtained results, which are depicted in Figure 3.1, did not show significant 
reduction in busulfan concentration in the incubation mixture compared to the 
control (no NADPH). 
 Apparent Michaelis-Menton kinetics was calculated (Km = 752 µM and 
Vmax = 1652 nmole/min/mg protein) for the conversion of 1-chloro-2,4-
dinitrobenzene to 2,4-dinitrophenyl-S-glutathione in the presence of human liver 
cytosol and glutathione (Figure 3.2). Ethacrynic acid as a positive control showed 
strong inhibitory effect on GST activity toward 1-chloro-2,4-dinitrobenzene. 
Ketoconazole showed a slight inhibitory effect on the activity of GST toward 1-





















Aroclor-1254 induced rat liver microsomes
 
 
Figure 3.1. Busulfan substrate disappearance studies. Each bar represents the ratio 
between busulfan concentration in the incubation mixture to its concentration in 
the control incubations (no NADPH). Values represent triplicate runs and error 




































Figure 3.2. Enzymatic conversion of 1-chloro-2,4-dinitrobenzene to 2,4-
dinitrophenyl-S-glutathione in human liver cytosol. Each point represents the 






































 0 µM ketoconazole
 100 µM ketoconazole
 250 µM ketoconazole
 
 
Figure 3.3. Inhibition of glutathione-S-transferase in human liver cytosol by 
ketoconazole. Each point represents the average of duplicate runs.  
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3.2 Sulfonium Ion Conjugate of Busulfan  
3.2.1 Synthesis of γ-Glutamyl-β-(S-tetrahydrothiophenium)alanylglycine (γ-E-
THT-AG)  
 The glutathione sulfonium conjugate was synthesized and subsequently 
purified by semi-preparative HPLC (percent yield = 11.1%). An ESI-MS scan of 
the purified product showed an M+ ion with m/z 362. MS/MS produced two 
daughter ions m/z 274.1 corresponding to the loss of tetrahydrothiophene, and  
m/z 145.2 consistent with the neutral loss of tetrahydrothiophene and pyroglutamic 
acid (Figure 3.4). The NMR spectrum and proton assignments were consistent 










Figure 3.4. MS/MS of γ-glutamyl-β-(S-tetrahydrothiophenium)alanylglycine. Loss 
of tetrahydrothiophene (m/z 274.1), loss of glycine and tetrahydrothiophene (m/z 
199.1), loss of tetrahydrothiophene and pyroglutamic acid (m/z 145.2). 
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3.2.2 Stability of γ-E-THT-AG  
γ-E-THT-AG undergoes a facile non-enzymatic β-elimination reaction 
which is expected to generate a glutathione analogue in which a cysteine moiety is 
replaced by a dehydroalanine residue. In agreement with this expectation, 
incubation of γ-E-THT-AG in 100 mM potassium phosphate buffer (pH 7.4 and 
8.0) for 6 h at 37 °C resulted in the disappearance of the conjugate (Figure 3.5). 
The loss of γ-E-THT-AG was more pronounced at pH 8.0 than at pH 7.4. In 
another experiment, γ-E-THT-AG (57 mM) was incubated in D2O – 100 mM 
phosphate buffer (pD ~ 8.0) for 12 hours at 37 °C. The formation of γ-
glutamyldehydroalanylglycine as a degradation product of γ-E-THTP-AG was 
confirmed by the appearance of vinylic protons as a doublet at 5.76 and 5.80 ppm 
in the 1H NMR spectrum. This instability of γ-E-THT-AG was verified by Dr. 
Arthur Cooper group by measuring the appearance of THT. Thus, when 75 μM γ-
Ε-THT-AG was incubated at 37 °C in 1 mL of potassium phosphate buffer (pH 
7.4) or phosphate buffer (pH 8.0) in 1.5-mL screw cap septum vials, the amount of 
THT present in solution at 6 h as measured by the HPLC-CoulArray procedure 
was 27.8 ± 0.8 and 41.0 ± 0.3 nmol/mL, respectively (n = 3). The data show that 
by 6 h ~50% and >90% of γ-E-THT-AG were converted to THT at pH 7.4 and pH 
8.0, respectively. This estimate agrees well with the amount of γ-E-THT-AG 
remaining at 6 h as estimated by LC/MS/UV detection. These findings verify the 
































Figure 3.5. Stability of γ-glutamyl-β-(S-tetrahydrothiophenium)alanylglycine (γ-E-
THT-AG) at pH 7.4 and pH 8.0. The data points are the average of two 
determinations. 
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3.2.3 Relative Alkylation Reactivity of γ-E-THT-AG  
 The alkylating reactivity of γ-E-THT-AG, in the concentration range of 
0.25-10 mg/mL, was compared to that of busulfan using 4-(4-nitrobenzyl)-
pyridine (NBP). Thio-TEPA was used as a positive control. Upon alkalinization, 
the alkylated NBP product that was formed generated a purple colored complex, 
which was quantified spectrophotometerically at 580 nm. γ-E-THT-AG did not 
react with NBP and no color formation was observed. On the other hand, busulfan 
produced a purple color and the intensity of the color increased with increasing 
concentration of busulfan (Figure 3.6). The intensity of the color produced by thio-
TEPA was 10 fold higher than that produced by busulfan at the same 
concentration (data not shown). 
3.2.4 Cytotoxicity of γ-E-THT-AG 
 The ability of γ-E-THT-AG to induce apoptosis was assessed using human 
liver cancer epithelial NCI-H460 cells. In addition, the percent apoptosis induced 
by γ-E-THT-AG was compared to that induced by the parent drug busulfan. γ-E-
THT-AG ion induced 5 % apoptosis at 400µg/mL compared to the control while 
busulfan induced 30% apoptosis at the same concentration. The percent induction 
of apoptosis was increased with increasing the busulfan concentration; on the 
other hand, increasing γ-E-THT-AG concentration did not significantly increase 



























Figure 3.6. Reactivity of busulfan and γ-E-THT-AG with 4-(4-nitrobenzyl)-

























Figure 3.7. Percent apoptosis induced by busulfan and γ-E-THT-AG in NCI-H460 
cells. 
 52
3.2.5 Effect of γ-E-THT-AG on glutathione-S-transferase (GST) 
.As depicted in Figure 3.8, γ-E-THT-AG in the concentration range (1-100 
µM), did not inhibit glutathione-S-transferase catalytic activity measured by 
assessing the rate of formation of 2,4-dintrophenyl-S-glutathione adduct in the 
presence of human liver cytosol. Ethacrynic acid (2.5-100 µM) was used as a 
positive control and showed concentration dependent inhibition of the glutathione-
S-transferase activity. 
Substrate Concentration (µM )





















Figure 3.8. Inhibitory effect of γ-E-THT-AG on the catalytic activity of glutathione-S-
transferase in human liver cytosol. Each point of γ-E-THT-AG curve represents the mean 
of triplicate determinations, and the error bars represent standard deviations. Ethacrynic 
acid was used a positive control, each point represent the average of two determinations. 
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3.3 Busulfan-Cysteine Sulfonium Ion Conjugate  
3.3.1 Synthesis of S-(β-alanyl)tetrahydrothiophenium (THT-A) 
THT-A was synthesized by the reaction of cysteine and 1-bromo-4-
chlorobutane. The product was crystallized from acetone (percent yield = 47.8%). 
The full scan spectrum of conjugate shows only a high intensity ion peak M+ with 
m/z of 176 corresponding to the mass of THT-A, suggesting that the final product 
was pure, which was verified by 1H NMR spectral analysis.  
The ESI- MS/MS spectrum of THT-A (Figure 3.9) showed one daughter 











Figure 3.9. MS/MS of S-β-alanyltetrahydrothiophenium (THT-A); m/z 176 
consistent with the molecular mass of THT-A; m/z 88 consistent with the loss of 
tetrahydrothiophene. 
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3.3.2 Chemical Stability of THT-A 
Το determine if ΤΗΤ-A undergoes a facile non-enzymatic β-elimination 
reaction to yield tetrahydrothiophene and dehydroalanine, THT-A was incubated 
at 37 ºC in 100 mM potassium phosphate buffer (pH 7.4 and 8.0) for 6 hours. The 
conjugate did decompose over 6 hours at both pH by less than 5% (Figure 3.10). 
This small amount of decomposition was observed by Dr. Cooper group through 
detecting the amount of THT formed. Thus, when 1 mM THT-A was incubated in 
1 mL of 100 mM potassium phosphate buffer at pH 7.4 or 8.0 (37 ºC) in 1.5-mL 
screw cap septum vials, the average percent of THT formed from THT-A at 0, 3, 
and 6 h was 3.77 %, 4.95 %, and 5.79 % (pH 7.4) and 4.09 %, 5.01 %, and 5.79 % 
(pH 8.0), respectively (n = 3 separate incubations). Thus, at pH 7.4, the initial rate 
of conversion of THT-A to THT is about 3% per 6 h at pH 7.4 (37 ºC). This value 
is in excellent agreement with the 2-4% loss per 6 h estimated from production of 
pyruvate and ammonium (control in Figure 3.14). Interestingly, the conversion of 
THT-A to THT at pH 8.0 is also quite slow (~3% per 6 h). By comparing these 
data with data in Figure 3.5, it appears that γ-E-THT-AG decomposes to THT 





























Figure 3.10. Stability of S-β-alanyltetrahydrothiophenium (THT-A) at pH 7.4 and 
pH 8.0 at 37 °C. The data points are the average of two determinations. 
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3.3.3 Reaction of cysteine with busulfan. 
 The chemical reactivity of busulfan with cysteine was determined by 
following the disappearance of busulfan with time in an incubation mixture 
containing a 400-fold molar excess of cysteine over busulfan in 100 mM 
potassium phosphate buffer (pH 8.0; 37 ºC). The results which are depicted in 
Figure 3.11 showed that busulfan disappeared slowly (K1pseudo = 0.0014 min-1) 
from the solution by a combination of hydrolysis and adduct formation (khydolysis = 
0.0007 min-1). Busulfan degradation is independent on the pH and decomposes at 
37 °C in 0.05 phosphate buffer (pH 7.0) to tertrahydrofuran and methanesulfonic 
acid with an apparent first order rate constant of 0.00072 min-1 (92). Our result is 
in conjugation with the reported value for the first order rate constant of busulfan 
degradation. The rate of disappearance of busulfan was doubled in the presence of 


























Figure 3.11. Reaction of busulfan with cysteine in 100 mM potassium phosphate 











3.3.4 Enzymatic Conversion of THT-A to Pyruvate and Ammonium 
Dr. Cooper and his coworkers evaluated the ability of two highly purified 
PLP-containing enzymes, namely glutamine transaminase K (GTK) and 
mitochondrial aspartate aminotransferase (AspAT), to catalyze a β-elimination 
reaction with THT-A. These enzymes are known to catalyze effective β-lyase 
reactions with halogenated cysteine S-conjugates such as DCVC and TFEC (83), 
and served as well-established reference cysteine S-conjugate β-lyases. However, 
no β-lyase activity toward THT-A with either GTK or mitAspAT was detected. 
Substantial β-lyase activity toward THT-A was found to be present in the 
liver homogenate, liver cytosol and liver mitochondrial fraction as measured by 
pyruvate formation (Figure 3.12). Clearly, the ability of kidney and brain 
homogenates to catalyze a β-lyase reaction with THT-A is much greater than that 
of the liver homogenate. This finding indicates that kidney and brain possess more 
enzymes that are capable of catalyzing β-elimination reactions with THT-A.  
The β-lyase activity toward THT-A was strongly, but not totally, inhibited 
by D,L-propargylglycine in the rat liver homogenate and cytosolic fraction. D,L-
Propargylglycine also significantly inhibited the β-lyase activity in the 
mitochondrial fraction, but proportionately less so than in the cytosol and 
homogenate (Figure 3.13). Since D,L-propargylglycine completely inhibits 
cystathionine γ-lyase, the data hypothesize that the enzymes cystathionine γ-lyase 
plus other β-lyases contribute to β-lyase activity with THT-A in rat liver fractions. 
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Figure 3.14 displays the ability of purified cystathionine-γ-lyase to catalyze 
a β-elimination reaction toward THT-A. The rate of formation of pyruvate and 
ammonium was significantly enhanced when THT-A was incubated with purified 
cystathionine-γ-lyase compared to the control (no enzyme). The effectiveness of 
the liver cytosol in catalyzing a β-elimination reaction with 5 mM THT-A relative 
to the rate at which the cytosol catalyzes a γ-elimination reaction with 20 mM L-
homoserine is about 1.20: 100. As noted above, this ratio for the purified enzyme 
is about 1.55:100. Therefore, within the experimental error of the procedures, the 
data indicate that cystathionine γ-lyase is the major β-lyase in rat liver cytosol 
acting on THT-A. However, a small fraction (~ 30%) of the β-lyase activity 
toward THT-A in the liver cytosol must be due to enzymes other than 
cystathionine γ-lyase as evidenced by activity that is propargylglycine-insensitive. 
 The specific activity of the purified rat liver cystathionine γ-lyase (0.55 
mg/mL) toward 20 mM L-homoserine is 2,400 nmol/min/mg of protein. The 
specific activity of this enzyme as a β-lyase with 5 mM THT-A as substrate was 
found to be 37.1 ± 0.37 nmol/min/mg of protein (n = 4). Thus, the rate at which 
cystathionine γ-lyase catalyzes a β-elimination reaction with 5 mM THT-A is 
about 1.55% the rate at which the enzyme catalyzes a γ-elimination reaction with 































Figure 3.12. β-lyase activity toward S-β-alanyltetrahydrothiophenium (THT-A) in 
rat liver, brain, and kidney homogenates. Each bar represents the average of 































Figure 3.13. β-lyase activity toward S-β-alanyltetrahydrothiophenium (THT-A) in 
rat liver homogenate, cytosol, and mitochondria. The activity is measured in the 
presence and absence of D,L-propargylglycine, a potent inhibitor of the enzyme 
cystathionine-γ-lyase. Each bar represents the average of three determinations, 
with the error bars representing standard deviation. 
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Figure 3.14. Non-enzymatic and enzymatic degradation of THT-A. Ammonium (top 
panel) and pyruvate (bottom panel) formation via β-elimination reactions with THT-A. 
Each point represents the average of three determinations, with error bars representing 
standard deviation. 
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3.4 γ-Glutamyldehydroalanylglycine (dehydroglutathione) 
3.4.1 Synthesis of dehydroglutathione  
 The synthesis of dehydroglutathione was carried in two steps; the first step 
was the synthesis of the precursor 2,4-dinitrophenyl-S-glutathione, which was 
prepared through the reaction of 1-chloro-2,4-dinitrobenzene with reduced 
glutathione. After recrystallization from hot water, a yellow crystalline material 
was obtained (yield 42.5%). The structure of the compound was confirmed by 1H 
NMR spectroscopy, and mass spectrometry. ESI-MS of the compound gave a 
molecular ion species (MH+) with m/z 473 consistent with the molecular mass of 
the product. The structure of the compound was further confirmed by multistage 
mass spectrometry. MS/MS of the molecular species of the compound produced a 
protonated daughter ion with m/z of 345 consistent with the neutral loss of 
pyroglutamic acid. 1H and COSY NMR spectra of the product are depicted in 
Figures 3.15 and 3.16, respectively. The proton assignments and the structure of 
the product are shown in Table 1. 
 Dehydroglutathione was synthesized through the base-catalyzed 
elimination of thiophenolate ion form 2,4-dinitrophenyl-S-glutathione. It is worth 
noting that increasing the time of mixing of the starting material in base produced 
many impurities that are difficult to remove, mixing for thirty minutes resulted in a 
relatively good yield and limited the impurities in the final product. Multiple 
extractions with sec-butanol were necessary to remove colored impurities. Passage 
through cation exchange resin was performed to remove sodium ions. After 
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evaporating the aqueous layer, a gold colored precipitate was obtained (yield 
60.4%). The ESI-MS full spectrum of the compound gave a high intensity ion 
peak (MH+) with m/z of 274. The formation of dehydroglutathione was further 
confirmed by 1H NMR (Figure 3.17), which shows the doublet of the vinylic 
protons centered at 5.62 ppm. The integration of the peaks in the spectrum shows 
that the obtained product is ~ 90% pure, which was confirmed by a quantitative 
13C NMR experiment. Further purification of the product using charcoal and/or 
crystallization with ethanol did not improve the purity of the compound. The data 
obtained from HETCOR NMR spectrum (Figure 3.18) suggested that the 
impurities are not carbon based. 
Position Chemical Shift (ppm) 
S CH2 CH CO NH CH2 COOH 
NO2
O2N
NH CO CH2 CH2 CH COOH
NH3
9    10 
6     7       8
11
12 13
5       4      3           2       1  
5           4  3            2       1  
CH2 C CO NH CH2 COOH
NH CO CH2 CH2 CH COOH
NH3
6     7       8
9    10 
S-2,4-dinitrophenylglutathione (DNPGSH)
γ-glutamyldehydroalanylglycine (dehydroGSH)
DNPGSH¶ dehydroGSH ¥ 
2 3.73 3.93 
4 4.46  
5 3.35 5.6 
7 2.3 2.48 
8 1.85 2.08 
9 3.63 3.46 
11 8.86  
12 7.79  
13 8.47  
   
   
   
   
 
Table 3.1. NMR spectral proton assignments of 2,4-dinitrophenyl-S-glutathione 
(DNPGSH), and γ-glutamyldehydroalanylglycine (dehydroGSH). DNPGSH was 














Figure 3.17. 1H NMR spectrum of γ-glutamyldehydroalanylglycine 
(dehydroglutathione). The compound is characterized by the vinylic protons 






Figure 3.18. HETCOR NMR spectrum of γ-glutamyldehydroalanylglycine 
(dehydroglutathione). 
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3.4.2 Reactivity of Dehydroglutathione Toward Nucleophiles 
 Dehydroglutathione contains an α,β−unsaturated system which makes it a 
Michael acceptor. Michael acceptor is generally referred to as the electrophile 
which reacts with a nucleophile to form a conjugate or adduct. We tested the 
ability of dehydroglutathione to form adducts with cellular nucleophiles such as 
glutathione and cysteine. Dehydroglutathione was incubated with cysteine in 1% 
NH4OH overnight and the crude reaction mixture was analyzed by mass 
spectrometry. The ESI-MS full scan of the mixture showed a protonated molecular 
species (MH+) with m/z of 396 consistent with molecular mass of the cysteine-
dehydroglutathione adduct. Fragmentation of the adduct by MS/MS produced a  
daughter ion with m/z 267 consistent with the neutral loss of pyroglutamic acid 
(data not shown). Further fragmentation of the daughter ion produced protonated 
molecular species with m/z 249 and m/z 192 corresponding to the loss of water and 
glycine, respectively (data not shown).  
 The observed second order reaction rate constant for the formation of the 
cysteine-dehydroglutathione adduct was determined by following the 
disappearance of the vinylic proton doublet in the 1H NMR spectrum. Cysteine 
and dehydroglutathione solution, prepared in 100 mM potassium phosphate buffer 
in deuterium oxide (pD 8.0), were mixed in equal molar concentrations and the 
reaction was carried out in NMR tube maintained at 37 ºC in the NMR probe. 
Figure 3.19 shows the plot of the reciprocal of the dehydroglutathione 
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concentration versus time. The slope of this curve which represents the observed 
second order rate reaction constant was determined to be 2.9 mM-1 min-1. 
  The formation of glutathione-dehydroglutathione adduct 
(lanthionylglutathione) was studied in the same manner as for the cysteine-
dehydroglutathione adduct described above. Structure elucidation of the adduct 
was obtained by single stage and multistage mass spectrometry. The full spectrum 
of the reaction mixture produced a protonated molecular species (MH+) with m/z 
581, which is consistent with molecular mass of the adduct. MS/MS of the adduct 
produced three daughter ions with m/z 563, m/z 452, and m/z 323 consistent with 
the neutral loss of water, pyroglutamic acid, and two molecules of pyroglutamic 
acid, respectively (Figure 3.20). The daughter ion m/z 323 was also obtained upon 
the fragmentation of the daughter ion m/z 452, which also produced a weak ion 
m/z 248 consistent with the neutral loss of glycine. 
3.4.3 In Vitro Cytotoxicity of Dehydroglutathione 
 C6 cell exposed to 0.25 mM- 2.0 mM of dehydroglutathione for 24 h 
displayed abnormal cell morphology characterized by cell shrinkage and the loss 
of cell processes. No such morphological changes were observed in C6 cells not 
treated with dehydroglutathione. Following 24 h of exposure to 
dehydroglutathione, there was a profound decrease in the number of viable cells. 
When compared to busulfan, dehydroglutathione produced less cytotoxicity (~ 
50%) at the same molar concentration (Figure 3.21). The LD50 values were 
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Figure 3.19. The second order reaction between cysteine and γ-
glutamyldehydroalanylglycine (dehydroglutathione) in 100 mM potassium 
phosphate buffer (pH 8.0). Each point represents the average of duplicate runs (n = 
2). 
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Figure 3.20. MS/MS of the glutathione- dehydroglutathione adduct. The adduct 
m/z 581, loss of water m/z 563, loss of pyroglutamic acid m/z 452, loss of two 















Figure 3.21. Busulfan and γ-glutamyldehydroalanylglycine (dehydroglutathione) 
cytotoxicity against C6 cells. Each point represents the average of three 
determinations. The LD50 values were approximately 460 µM and 880 µM for 
busulfan and dehydroglutathione, respectively. 
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3.5 Effect of N,N-Dimethylacetamide (DMA) on the Catalytic Activity of 
CYP450 3A4, 2B6, and 2C9 in Human Liver Microsomes 
3.5.1 CYP3A4 Assay 
Testosterone 6β-hydroxylation was measured to determine the catalytic 
activity of the CYP3A4 enzyme in human liver microsomes (93). The formation 
of 6β-hydroxytestosterone did not vary from the control when the microsomes 
were co-incubated with DMA (Figure 3.22, panel A). The results suggested that 
DMA is not a competitive inhibitor of CYP3A4. 
3.5.2 CYP2B6 Assay 
Bupropion hydroxylation has previously been shown to be a marker for 
CYP2B6 activity in humans (94). The rate of hydroxylbupropion formation was 
not affected when DMA (0-25mM) was added to the incubation mixture (Figure 
3.22, panel B). When compared to thio-TEPA, a known CYP2B6 specific 
inhibitor (95), DMA did not produce significant inhibition on the catalytic activity 
of CYP2B6.  
3.7.3 CYP2C9 Assay 
Tolbutamide methylhydroxylation was measured to determine the effect of 
DMA on the catalytic activity of CYP2C9 (96). As depicted in panel C of Figure 
3.22, DMA did not inhibit CYP2C9 catalytic activity in the concentration range 0-
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Figure 3.22. Effect of DMA on the catalytic activity of CYP40 in human liver 
microsomes. Panel A testosterone 6β-hydroxylation (CYP3A4); panel B, bupropion 
hydroxylation (CYP2B6); panel C, tolbutamide 4-methylhydroxylation (CYP2C9). The 






Chapter 4: Discussion 
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Metabolism of busulfan: The major elimination pathway of busulfan is through 
conjugation with glutathione. Some literature data suggested a possible 
involvement of CYP450 in the metabolism of busulfan (23-25,97). Our results 
clearly showed that busulfan is not a substrate for CYP450. The observed increase 
in busulfan clearance upon the co-administration of drugs that are known to induce 
CYP450 is more likely caused by increased elimination of busulfan by pathways 
other than CYP450 mediated metabolism. Fitzsimmons et al reported that 
anticonvulsants such as phenytoin and phenobarbital protect from the acute 
neurotoxicity, and increase the survival rate from myelotoxicity caused by 
busulfan(97). Phenytoin induces γ-glutamyltransferase (44), this enzyme has a 
wide substrate specificity and can convert the glutathione S-conjugate of busulfan 
to its corresponding cysteinylglycine S-conjugate. It is also possible that these 
enzyme inducers induce microsomal GST which provides protection against 
busulfan toxicity (98). On the other hand, our results suggest that the slight 
reduction in busulfan clearance (~20 %) observed upon using ketoconazole along 
with busulfan, can be attributed in part to the weak inhibitory effect of 
ketoconazole on GST activity. The obtained results support the idea that 
glutathione conjugation is the only pathway for busulfan clearance, and that 
observed changes in busulfan clearance can be attributed to changes in this 
pathway. It should be noted that one can not rule out the substrate inhibition of 
CYP450 in the liver microsomes at 1 µM of busulfan. Hassan et al reported that 
busulfan significantly reduced the clearance, increased the elimination half-life, 
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and reduced the exposure to the cytotoxic metabolites of cyclophosphamide (99). 
These findings suggest the ability of busulfan to inhibit CYP450 3A4, 2C9, and 
2B6 which are necessary for the bioactivation of cyclophosphamide. 
 Busulfan is converted to the glutathione S-conjugate (L-γ-glutamyl-β-(S-
tetrahydrothiophenium)-L-alanylglycine (γ-E-THT-AG) non-enzymatically(100) 
and by GST, especially GSTA-1 (41,42,100). Several studies have shown that 
major urinary metabolites of busulfan are sulfolane [tetrahydrothiophene 1,1-
dioxide], 2-hydroxysulfolane, 3-hydroxysulfolane, and tetrahydrothiophene 1-
oxide (26,37,91,101). These findings indicate that busulfan is metabolized to 
tetrahydrothiophene (THT), which is subsequently readily oxidized in vivo at the 
sulfur, and at the 2- and 3-positions of the ring. γ-E-THT-AG has been shown to 
undergo a non-enzymatic β-elimination reaction yielding THT under alkaline 
conditions (91) (Figure 1.1). 
Two possible mechanisms for non-enzymatic production of THT from γ-E-
THT-AG; one would be through SN2 hydrolysis by direct attack at the acyclic 
methylene attached to the sulfur to produce THT and γ-glutamylserinylglycine 
(Figure 4.1, A) and the other would be through E1 type reaction (β-elimination) 
that is a base catalyzed elimination of THT by the abstraction of the α proton, 
which will lead to the formation of THT and γ-glutamyldehydroalanylglycine 
(Figure 4.1, B). Our data show that in addition to THT, a product observed by 










































Figure 4.1. Proposed mechanisms of non-enzymatic degradation of L-γ-glutamyl-
β-(S-tetrahydrothiophenium)-L-alanylglycine (γ-E-THT-AG), SN2 hydrolysis (A), 
β-elimination (B). 
 
γ-E-THT-AG is γ-glutamyldehydroalanylglycine. This non-enzymatic reaction 
takes place at a slow but measurable rate under physiological conditions (pH 7.4 
and 37 °C). Thus, there seems little doubt that THT can be formed non-
enzymatically in vivo from γ-E-THT-AG. The question remains as to which 
enzymes such as β-lyases, also contribute to THT formation from γ-E-THT-AG in 
vivo. Ritter et al (100) stated “the sulfonium product can be cleaved to THT either 
enzymatically, for example, by β-lyases or chemically by alkalization”. We are 
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unaware of precedence for GST or other enzymes catalyzing β-elimination 
reactions with glutathione S-conjugates. A more likely substrate for an enzyme-
catalyzed β-lyase reaction in the busulfan metabolic pathway is the cysteine S-
conjugate (THT-A) rather than the glutathione S-conjugate (γ-E-THT-AG). 
Since the enzymes that convert glutathione S-conjugates to cysteine S-
conjugates (i.e. γ-glutamyltransferase and dipeptidase/cysteinylglycinase) have a 
wide substrate specificity (85,102), it is probable that γ-E-THT-AG will be 
converted in vivo to the corresponding cysteine S-conjugate [β-(S-
tetrahydrothiophenium)-L-alanine, THT-A] by these enzymes. THT-A can be 
either converted to an N-acetylcysteine conjugate or undergo a β-elimination 
reaction. The identification of the N-acetylcysteine conjugate of busulfan in rat 
urine treated with busulfan confirms the existence of this pathway in vivo (39). It 
should also be noted that THT-A may also be formed non-enzymatically. Our 
reasoning is based on the nucleophilic reactivity of sulfhydryl compounds with 
busulfan. GSH reacts with busulfan at pH 7.4 (84). Because the pKa value of the -
SH group in cysteine is lower than that of the -SH group in GSH (8.2-8.5 versus 
9.2) (103), the cysteine sulfhydryl is a more reactive nucleophile than is the GSH 
sulfhydryl at physiological pH values. 
Our data showed that cysteine can react non-enzymatically with busulfan to 
generate THT-A at pH 8 and 37 ºC. Thus, some THT-A is probably formed in vivo 
by the non-enzymatic reaction of endogenous cysteine with busulfan. However, 
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the predominant route for formation of THT-A in vivo is likely to be enzyme 
catalyzed. We hypothesize that although a portion of γ-E-THT-AG is converted 
non-enzymatically to THT and γ-glutamyldehydroalanylglycine, the major 
metabolic fate of γ-E-THT-AG in liver and other organs in vivo is conversion to 
THT-A by the consecutive action of γ-glutamyltranspeptidase and 
dipeptidase/cysteinylglycinase. We further hypothesize that THT-A is then 
converted to THT in part non-enzymatically, but for the most part by cysteine S-
conjugate β-lyases.  
The Vmax and Km values for human liver cytosol-catalyzed formation of 
THT from busulfan in the presence of 0.7 mM GSH were reported to be 134 pmol 
mg protein-1 min-1 and 2.74 mM, respectively (100). In the present work, we 
showed that the rate at which rat liver cytosol catalyzes a β-lyase reaction with 5 
mM THT-A (~1.06 nmol mg protein-1 min-1) is considerably faster than the rate at 
which human liver cytosol can maximally convert busulfan to THT. We also 
showed that rat liver mitochondria and homogenates of rat brain and kidney also 
catalyze a β-lyase reaction with THT-A. Busulfan is capable of crossing the brain 
blood barrier (104). Thus, the potential exists for prominent metabolism of 
busulfan via cysteine S-conjugate β-lyase reactions in multiple organs including 
the brain. Furthermore, we have identified a major β-lyase acting on THT-A in rat 
liver cytosol as cystathionine γ-lyase. Our data also suggest that other enzymes are 
also capable of catalyzing this reaction in rat liver mitochondria, brain and kidney. 
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The identity of these enzymes must await further study. However, two PLP-
containing enzymes that catalyze prominent β-lyase reactions with halogenated 
cysteine S-conjugates, namely GTK and mitAspAT were ruled out as candidates. 
Toxicity of busulfan and its metabolites: Conditioning therapy with cytotoxic 
drugs, such as busulfan and cyclophosphamide, in patients undergoing bone 
marrow transplant is the most important factor leading to the development of 
hepatic venoocclusive disease (HVOD) (105-109). HVOD is caused by the 
destruction of sinusoidal endothelial cells and the surrounding centriobular 
hepatocytes (110,111). This effect is observed more often in patients with high 
systemic exposure to the parent drug, whereas efficacy may be compromised in 
those with low systemic exposure (107,112). Monitoring of the prospective 
busulfan plasma disposition and dose individualization may reduce the frequency 
of HVOD in some, but not all, patients (113). It was proposed that HVOD 
associated with conditioning regimens of busulfan in bone transplant patients is 
related to the metabolites of busulfan rather than the parent compound (114). 
DeLeve et al suggested that this complication can be caused either directly through 
oxidative stress or indirectly through glutathione depletion (115). We hypothesize 
that these conditions are related in part to the non-enzymatic decomposition of the 
glutathione S-conjugate γ-E-THT-AG to γ-glutamyldehydroalanylglycine. 
Dehydroalanine-containing peptides are well known in nature and have 
been recognized as excellent Michael acceptors that can link biologically active 
molecules to a variety of cellular targets. For example, dehydroalanine is present 
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in lantibiotics, a class of ribosomally synthesized peptide antibacterial agents. 
Michael addition of a sulfhydryl to the double bond of a dehydroalanine residue 
can occur readily. In fact, many of the lantibiotics possess lanthionine residues, 
that are formed though Michael addition of a cysteine sulfhydryl group to the 
double bond of a dehydroalanine residue (reviewed in (116)). A similar addition 
reaction to a Michael acceptor is hypothesized to occur in the human lens. Thus, 
lanthionine residues are associated with aging of the human lens and 
cataractogenesis (117). These lanthionine residues appear to be due in part to non-
reducible thioethers formed from glutathione. Linetsky and LeGrand (117) 
reasonably considered that the non-reducible glutathionylation is due to Michael 
addition of the sulfhydryl moiety of GSH to dehydroalanine residues formed 
within lens proteins. Our data suggest, however, that non-reducible 
glutathionylation could also occur through addition of γ-
glutamyldehydroalanylglycine to the cysteine moiety of a susceptible protein. 
Presumably, γ-glutamyldehydroalanylglycine formation is not of primary 
significance during normal physiological aging. However, formation of γ-
glutamyldehydroalanylglycine may be a critical factor/toxicant in individuals 
treated with busulfan, not only in regard to the lens, but also to the circulatory 
system in general. Interestingly, it has recently been shown that busulfan treatment 
of mice resulted in upregulation of glutathione synthesis and increased toxicity of 
busulfan (118). We suggest that higher GSH levels lead to higher concentrations 
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of γ-E-THT-AG. An increase in γ-E-THT-AG would lead to increased non-
enzymatic formation of γ-glutamyldehydroalanylglycine, which in turn, would 
lead to non-reducible glutathionylation of proteins associated with the circulatory 
system. This could be confirmed by the observed reduction in the neurotoxicity 
and myelotoxicity of busulfan when it is co-administered with phenytoin (97). 
Phenytoin induces  γ-glutamyltransferase (44) which in turn will reduce the 
amount of γ-glutamyldehydroalanylglycine formed. Our data shows the ability of 
γ-glutamyldehydroalanylglycine to undergo Michael additions with free cysteine 
and with GSH. It is possible that the Michael adducts of γ-
glutamyldehydroalanylglycine with cysteine and GSH will interfere with enzymes 
that utilize GSH/glutathione disulfide as substrates. We suggest that increased 
non-reducible glutathionylation of proteins and Michael adducts with GSH and 
free cysteine may contribute to busulfan-induced cataract formation and HVOD. If 
that is the case, then regimens or strategies designed to either deplete endogenous 
GSH levels with co-administration of ethacrynic acid (cf.(41)) or accelerate the 
conversion of the glutathione S-conjugate to the cysteine S-conjugate should be 
protective. Detoxification would be complete when the cysteine S-conjugate is 
converted to the relatively harmless products pyruvate, THT and ammonium via 
β-lyase reactions catalyzed by cystathionine γ-lyase and/or other PLP-containing 
enzymes. It is also possible that high doses of vitamin B6 might be beneficial in 
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promoting the conversion of THT-A to THT in patients undergoing treatment with 
busulfan. 
Harkey et al. (98) recently showed that overexpression of a microsomal 
GST (MGSTII) in HEK human kidney fibroblasts confers protection against 
busulfan and melphalan. At first glance, this finding is not in agreement with our 
hypothesis. Indeed, the authors suggested that formation of the glutathione S-
conjugate is protective against busulfan toxicity. However, the authors showed 
that overexpression of GSTA1 and GSTP1 in these cells is not protective, yet as 
noted above, these GST catalyze the formation of γ-E-THT-AG from busulfan. 
Moreover, MGSTII does not have the ability to conjugate GSH to busulfan (41). 
Harkey et al. (98) discuss the possibility of involvement of other enzymes and the 
ABC transporter MRP1 (a major transporter of glutathione conjugates from cells) 
in contributing to protection against busulfan. It would be interesting to determine 
whether overexpression of MGSTII also leads to increased levels of γ-
glutamyltranspeptidase and dipeptidase/cysteinylglycinase. 
Safety of busulfan parenteral formulation: N,N-Dimethylacetamide (DMA) is a 
constituent of the solvent system used to solubilize busulfan in IV formulation. As 
a result, patients receiving high dose of busulfan are also exposed to high dose of 
DMA. We evaluated the effect of DMA on the catalytic activity of CYP450 2B6, 
2C9, and 3A4 using human liver microsomes and substrate markers. Bupropion, 
tolbutamide, and testosterone were used as substrate marker to assess the catalytic 
activity of CYP450 2B6, 2C9, and 3A4, respectively. These three isoform were 
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chosen cause of their role in the activation of cyclophosphamide, an anti-cancer 
agent used along with busulfan in high doses for conditioning patients prior to 
bone marrow transplant. 
.The DMA concentration range used (5 µM- 25 mM) took into account the 
minimum amount of DMA detected in the urine of workers occupationally 
exposed to the solvent (119), and the maximum amount of DMA delivered to the 
body in busulfan IV formulation. Our results indicated no inhibitory effect of 
DMA on the catalytic activity of CYP450 2B6, 2C9, 3A4. This supports the safety 
of using DMA in busulfan formulation, and indicates no drug-drug interaction 
associated with DMA and cyclophosphamide. The obtained results are in 
agreement with the work of Andersson et al (120), where the safety of using IV 
busulfan along with cyclophosphamide as pretransplantation conditioning therapy 
was indicated. 
Though the current work showed no inhibitory effect of DMA on the 
aforementioned CYP450 isoforms, DMA is known to inhibit CYP450 2E1 (72). 
DMA should not be used to solubilize drugs that are co-administered with 











Chapter 5: Summary and Conclusion 
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The major biotransformation pathway in the metabolism of busulfan involves 
the glutathione-derived formation of THT. Although busulfan contains two sulfur 
atoms, the sulfur of THT is not derived from busulfan, but rather from GSH. The 
glutathione S-conjugate of busulfan (γ-E-THT-AG) undergoes a non-enzymatic 
elimination reaction to generate THT and γ-glutamyldehydroalanylglycine. We 
hypothesize that γ-glutamyldehydroalanylglycine contributes to the toxicity of 
busulfan by forming Michael adducts with protein cysteinyl residues, free cysteine, 
GSH and Coenzyme A. Here we show that rat tissues contain enzymes, one of 
which was identified as cystathionine γ-lyase, that are capable of converting the 
cysteine S-conjugate of busulfan (THT-A) to pyruvate, THT and ammonium. The β-
lyase reaction is likely a detoxification mechanism. The results suggest that THT 
either is formed non-enzymatically from γ-E-THT-AG or through the mercapturic 
acid pathway and β-lyase catalysis involving THT-A as an intermediate. Stimulation 
of this pathway may afford protection against busulfan toxicity. 
We have constructed the most likely pathways for the metabolism of 
busulfan to THT in vivo (Figure 5.1). The strong electron-withdrawing properties of 
the -OS(O2)CH3 group on busulfan (I) results in electron deficiency at each carbon 
adjacent to the two methanesulfonyl groups. This deficiency facilitates the 
nucleophilic attack of the sulfhydryl of glutathione at one of these carbons, resulting 
in elimination of methanesulfonate (II) and subsequent generation of adduct III. 
This step occurs non-enzymatically, but is accelerated by GST. The electron 
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deficiency in the remaining carbon adjacent to the -OS(O2)CH3 group in adduct III 
facilitates non-enzymatic intramolecular nucleophilic attack at this carbon by a pair 
of electrons on the sulfur of the thioether, generating the glutathione S-conjugate γ-
E-THT-AG (V) and eliminating a second equivalent of methanesulfonate. The 
conversion of busulfan (I) to γ-E-THT-AG (V) is shown as occurring by two 
consecutive steps but may occur by a concerted mechanism. The adduct γ-E-THT-
AG (V) possesses a cyclic sulfonium group. Owing to the broad specificity of γ-
glutamyltranspeptidase and dipeptidase, V is expected to be readily converted to the 
corresponding cysteine S-conjugate THT-A (VI) in vivo.  The adduct THT-A (VI) 
may also arise by non-enzymatic nucleophilic attack of a cysteine sulfur on busulfan 
(I), which generates adduct IV and methanesulfonate, followed by intramolecular 
cyclization and elimination of a second equivalent of methanesulfonate. The adduct 
THT-A (VI) contains a leaving group and is therefore expected to undergo a facile 
β-elimination reaction to yield THT (VII), pyruvate (VIII) and ammonium (IX). 
This reaction occurs non-enzymatically at pH 7.4, but is accelerated by PLP and by 
rat liver cystathionine γ-lyase (and by other as yet unrecognized enzymes in rat 
tissues). THT (VII) may also be generated directly and non-enzymatically from γ-E-
THT-AG (V) by an elimination reaction that results in the formation of γ-
glutamyldehydroalanylglycine (X). Michael addition of RSH (where RSH = 
cysteine, GSH, Coenzyme A or a cysteinyl residue of a protein) to γ-
 90
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